$OCUL
OCULAR THERAPEUTIX, INC

2023 Q4 Form 10-Q Financial Statement

#000155837023017989 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $14.80M $15.08M
YoY Change 5.16% 26.04%
Cost Of Revenue $1.386M $1.377M
YoY Change 36.96% 28.33%
Gross Profit $13.42M $13.70M
YoY Change 2.69% 25.82%
Gross Profit Margin 90.64% 90.87%
Selling, General & Admin $17.27M $17.90M
YoY Change -8.53% -4.37%
% of Gross Profit 128.74% 130.61%
Research & Development $16.20M $15.02M
YoY Change 19.58% 9.48%
% of Gross Profit 120.72% 109.6%
Depreciation & Amortization $958.0K $890.0K
YoY Change 95.11% 74.85%
% of Gross Profit 7.14% 6.49%
Operating Expenses $33.46M $32.92M
YoY Change 3.21% 1.49%
Operating Profit -$20.05M -$19.21M
YoY Change 3.56% -10.82%
Interest Expense -$9.170M $3.426M
YoY Change -340.12% 90.65%
% of Operating Profit
Other Income/Expense, Net $0.00 $18.70M
YoY Change -807.19%
Pretax Income -$29.22M -$520.0K
YoY Change 88.01% -97.85%
Income Tax
% Of Pretax Income
Net Earnings -$29.22M -$516.0K
YoY Change 88.01% -97.87%
Net Earnings / Revenue -197.42% -3.42%
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$0.33 -$0.25
COMMON SHARES
Basic Shares Outstanding 79.42M 79.38M
Diluted Shares Outstanding 85.14M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $195.8M $110.6M
YoY Change 91.4% -8.56%
Cash & Equivalents $195.8M $110.6M
Short-Term Investments
Other Short-Term Assets $7.944M $4.900M
YoY Change 97.22% 47.68%
Inventory $2.305M $2.257M
Prepaid Expenses
Receivables $26.18M $23.59M
Other Receivables $0.00 $0.00
Total Short-Term Assets $232.2M $141.3M
YoY Change 79.16% -2.99%
LONG-TERM ASSETS
Property, Plant & Equipment $11.74M $12.49M
YoY Change 19.11% 73.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.614M $1.800M
YoY Change -8.5% 2.04%
Total Long-Term Assets $19.83M $21.13M
YoY Change 0.83% 62.96%
TOTAL ASSETS
Total Short-Term Assets $232.2M $141.3M
Total Long-Term Assets $19.83M $21.13M
Total Assets $252.1M $162.4M
YoY Change 68.84% 2.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.389M $3.984M
YoY Change -14.33% -24.94%
Accrued Expenses $28.67M $28.89M
YoY Change 18.96% 33.65%
Deferred Revenue $255.0K $317.0K
YoY Change -55.73% -47.43%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.90M $35.07M
YoY Change 11.15% 19.81%
LONG-TERM LIABILITIES
Long-Term Debt $74.93M $73.90M
YoY Change 38.73% 38.53%
Other Long-Term Liabilities $108.0K $106.0K
YoY Change 16.13% -99.64%
Total Long-Term Liabilities $108.0K $106.0K
YoY Change 16.13% -99.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.90M $35.07M
Total Long-Term Liabilities $108.0K $106.0K
Total Liabilities $160.9M $154.5M
YoY Change 41.28% 37.54%
SHAREHOLDERS EQUITY
Retained Earnings -$697.6M -$668.4M
YoY Change 13.09% 11.15%
Common Stock $788.7M $676.2M
YoY Change 20.93% 4.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $91.13M $7.853M
YoY Change
Total Liabilities & Shareholders Equity $252.1M $162.4M
YoY Change 68.84% 2.4%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$29.22M -$516.0K
YoY Change 88.01% -97.87%
Depreciation, Depletion And Amortization $958.0K $890.0K
YoY Change 95.11% 74.85%
Cash From Operating Activities -$22.45M -$7.730M
YoY Change 32.41% -41.3%
INVESTING ACTIVITIES
Capital Expenditures $459.0K $260.0K
YoY Change -78.65% -132.75%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$459.0K -$260.0K
YoY Change -78.65% -67.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 108.2M 51.94M
YoY Change 23517.9% 13787.7%
NET CHANGE
Cash From Operating Activities -22.45M -7.730M
Cash From Investing Activities -459.0K -260.0K
Cash From Financing Activities 108.2M 51.94M
Net Change In Cash 85.26M 43.95M
YoY Change -557.14% -423.42%
FREE CASH FLOW
Cash From Operating Activities -$22.45M -$7.730M
Capital Expenditures $459.0K $260.0K
Free Cash Flow -$22.91M -$7.990M
YoY Change 19.91% -35.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2022Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001393434
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77201819
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79412114
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36554
dei Entity Registrant Name
EntityRegistrantName
Ocular Therapeutix, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5560161
dei Entity Address Address Line1
EntityAddressAddressLine1
24 Crosby Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
357-4000
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
79418626
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110550000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102300000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23589000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21325000
CY2023Q3 us-gaap Inventory Net
InventoryNet
2257000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1974000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4862000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4028000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
141258000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
129627000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12494000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9856000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6868000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8042000
CY2023Q3 us-gaap Assets
Assets
162384000
CY2022Q4 us-gaap Assets
Assets
149289000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3984000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5123000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28887000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24097000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
317000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
576000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1878000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1599000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
35066000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31395000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7251000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8678000
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
24022000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6351000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
14197000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13387000
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
65124000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25257000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
106000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
93000
CY2023Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
8765000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
28749000
CY2023Q3 us-gaap Liabilities
Liabilities
154531000
CY2022Q4 us-gaap Liabilities
Liabilities
113910000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79412114
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77201819
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
676203000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
652213000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-668358000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-616842000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
7853000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162384000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149289000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15081000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11965000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43642000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37419000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1377000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1073000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3895000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3528000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15019000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13719000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44860000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39919000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9315000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10186000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
31304000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
29390000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8584000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8531000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25915000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23875000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
34295000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
33509000
us-gaap Costs And Expenses
CostsAndExpenses
105974000
us-gaap Costs And Expenses
CostsAndExpenses
96712000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19214000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21544000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62332000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59293000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1212000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
285000
us-gaap Investment Income Net
InvestmentIncomeNet
2524000
us-gaap Investment Income Net
InvestmentIncomeNet
375000
CY2023Q3 us-gaap Interest Expense
InterestExpense
3426000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1797000
us-gaap Interest Expense
InterestExpense
7187000
us-gaap Interest Expense
InterestExpense
5175000
CY2023Q3 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
6722000
CY2022Q3 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-1133000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
1290000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
8598000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
14190000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
14190000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18698000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2644000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10816000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3797000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-516000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-24188000
us-gaap Net Income Loss
NetIncomeLoss
-51516000
us-gaap Net Income Loss
NetIncomeLoss
-55496000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79373272
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76975839
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78276341
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76829434
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85142504
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76975839
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84045573
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82598666
us-gaap Profit Loss
ProfitLoss
-51516000
us-gaap Profit Loss
ProfitLoss
-55496000
us-gaap Share Based Compensation
ShareBasedCompensation
13497000
us-gaap Share Based Compensation
ShareBasedCompensation
12730000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
4553000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3616000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
1290000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
8598000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2025000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1618000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
14190000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2264000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1333000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
834000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1433000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
283000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
295000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-73000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
501000
ocul Increase Decrease In Operating Lease Asset And Liability
IncreaseDecreaseInOperatingLeaseAssetAndLiability
26000
ocul Increase Decrease In Operating Lease Asset And Liability
IncreaseDecreaseInOperatingLeaseAssetAndLiability
-331000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2019000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-293000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
551000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1136000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47780000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42645000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5628000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1565000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5628000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1565000
ocul Proceeds From Issuance Of Protective Advance
ProceedsFromIssuanceOfProtectiveAdvance
2000000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
82474000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
543000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
514000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
418000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
482000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5184000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9532000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
26125000
ocul Repayment Of Protective Advance
RepaymentOfProtectiveAdvance
2000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61658000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
996000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8250000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-43214000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104064000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165928000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112314000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122714000
us-gaap Interest Paid Net
InterestPaidNet
2865000
us-gaap Interest Paid Net
InterestPaidNet
1521000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
267000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
477000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
78000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4572000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30318000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9711000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
403000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
418000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8824000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4413000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20682000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3087000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
62000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
708000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4512000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-516000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
7853000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
87999000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
129000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4209000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12542000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
79795000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
482000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4281000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18766000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
65803000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
374000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4240000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-24188000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
46229000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-668358000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110550000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;text-indent:18pt;margin:6pt 0pt 12pt 0pt;">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the measurement and recognition of reserves for variable consideration related to product sales, revenue recognition related to a collaboration agreement that contains multiple promises, the fair value of derivatives, stock-based compensation, and realizability of net deferred tax assets. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</p>
CY2023Q3 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2285000
CY2022Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1816000
CY2023Q3 ocul Accrued Interest Convertible Notes
AccruedInterestConvertibleNotes
10319000
CY2022Q4 ocul Accrued Interest Convertible Notes
AccruedInterestConvertibleNotes
8756000
CY2023Q3 ocul Accrued Interest Notes Payable
AccruedInterestNotesPayable
858000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13963000
ocul Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
1000000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
449000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14514000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110550000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120950000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112314000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122714000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
293000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
309000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
947000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
899000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1017000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
766000
CY2023Q3 us-gaap Inventory Net
InventoryNet
2257000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1974000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7862000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7509000
CY2023Q3 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
4679000
CY2022Q4 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
3560000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1347000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1228000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1537000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1228000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28887000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24097000
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
37500000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
37500000
CY2023Q3 ocul Debt Instrument Unamortized Discount And Current Portion
DebtInstrumentUnamortizedDiscountAndCurrentPortion
28735000
CY2022Q4 ocul Debt Instrument Unamortized Discount And Current Portion
DebtInstrumentUnamortizedDiscountAndCurrentPortion
8751000
CY2023Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
8765000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
28749000
CY2023Q3 ocul Royalty Fee Obligation
RoyaltyFeeObligation
-388000
ocul Royalty Fee Obligation
RoyaltyFeeObligation
-388000
CY2023Q3 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
6722000
CY2022Q3 ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
-1133000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
1290000
ocul Derivative Gain Loss On Derivative And Other Net
DerivativeGainLossOnDerivativeAndOtherNet
8598000
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
6351000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-5432000
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
11783000
CY2023Q3 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
827000
CY2023Q3 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
6317000
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
11384000
CY2023Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1004000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
3232000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
3425000
CY2023Q3 us-gaap Dilutive Securities
DilutiveSecurities
-22051000
us-gaap Dilutive Securities
DilutiveSecurities
-16619000
CY2023Q3 ocul Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsForfeituresAndExpirationsInPeriod
232939
ocul Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsForfeituresAndExpirationsInPeriod
793146
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4512000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4240000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13497000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12730000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
20573000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M20D
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-516000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-24188000
us-gaap Net Income Loss
NetIncomeLoss
-51516000
us-gaap Net Income Loss
NetIncomeLoss
-55496000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79373272
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76975839
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78276341
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76829434
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-516000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-51516000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55496000
us-gaap Dilutive Securities
DilutiveSecurities
-8598000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21563000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-64903000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-60669000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79373272
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78276341
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76829434
CY2023Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85142504
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84045573
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82598666
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17959906
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14846276
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17959906
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14846276

Files In Submission

Name View Source Status
0001558370-23-017989-index-headers.html Edgar Link pending
0001558370-23-017989-index.html Edgar Link pending
0001558370-23-017989.txt Edgar Link pending
0001558370-23-017989-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocul-20230930.xsd Edgar Link pending
ocul-20230930x10q.htm Edgar Link pending
ocul-20230930xex10d1.htm Edgar Link pending
ocul-20230930xex10d2.htm Edgar Link pending
ocul-20230930xex10d3.htm Edgar Link pending
ocul-20230930xex31d1.htm Edgar Link pending
ocul-20230930xex31d2.htm Edgar Link pending
ocul-20230930xex32d1.htm Edgar Link pending
ocul-20230930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ocul-20230930_cal.xml Edgar Link unprocessable
ocul-20230930_def.xml Edgar Link unprocessable
ocul-20230930_lab.xml Edgar Link unprocessable
ocul-20230930_pre.xml Edgar Link unprocessable
ocul-20230930x10q_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending